Clinical and radiographic presentations of COVID-19 among patients receiving radiation therapy for thoracic malignancies by Samson, Pamela et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
7-1-2020 
Clinical and radiographic presentations of COVID-19 among 
patients receiving radiation therapy for thoracic malignancies 
Pamela Samson 
Matthew S Ning 
Narek Shaverdian 
Annemarie F Shepherd 
Daniel R Gomez 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Pamela Samson, Matthew S Ning, Narek Shaverdian, Annemarie F Shepherd, Daniel R Gomez, Gwendolyn 
J McGinnis, Paige L Nitsch, Steven Chmura, Michael S O'Reilly, Percy Lee, Joe Y Chang, Clifford Robinson, 
and Steven H Lin 
Teaching Case
Clinical and Radiographic Presentations of
COVID-19 Among Patients Receiving Radiation
Therapy for Thoracic Malignancies
Pamela Samson, MD, MPHS,a,1 Matthew S. Ning, MD, MPH,b,1
Narek Shaverdian, MD,c Annemarie F. Shepherd, MD,c
Daniel R. Gomez, MD,c Gwendolyn J. McGinnis, MD, MS,b
Paige L. Nitsch, MS, DABR,b Steven Chmura, MD, PhD,d
Michael S. O’Reilly, MD,b Percy Lee, MD,b Joe Y. Chang, MD, PhD,b
Clifford Robinson, MD,a and Steven H. Lin, MD, PhDb,*
aDepartment of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, Missouri;
bDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas; cDepartment of Radiation Oncology,
Memorial Sloan Kettering Cancer Center, New York, New York; and dDepartment of Radiation Oncology, University of
Chicago, Chicago, Illinois
Received 20 April 2020; revised 23 April 2020; accepted 27 April 2020
Introduction
The novel coronavirus disease 2019 (COVID-19),
caused by the severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2), has led to a pandemic affecting
health care centers across the globe. With an estimated
case fatality rate of 3.5%1,2 and a wide range of age
groups affected, providers are rapidly adjusting their
patterns of care to mitigate the negative impact of infec-
tion to cancer patients. In particular, oncologic patients
have been reported to be at increased risk of infection and
at a greater risk of severe events.1 As such, patients
undergoing active cancer therapy are considered more
vulnerable to significant morbidity from COVID-19.3,4
The current management for COVID-19 is maximum
supportive care, and early diagnosis may help minimize
adverse outcomes among patients.5 However, asymp-
tomatic carriers may represent up to 42% of all infected
patients,6 confirmed by the observation of high viral titers
in the absence of symptoms.7,8 In addition, reverse tran-
scription polymerase chain reaction (RT-PCR) laboratory
testing has raised concerns regarding processing speed,
sensitivity, and availability.9 Thus, novel detection stra-
tegies are necessary to supplement traditional screening
methods and facilitate early diagnosis and mitigation of
viral transmission.
Indeed, recent data support the diagnostic consistency
and potential value of diagnostic computed tomography
(CT) scans to aid early diagnosis of COVID-19. Sensitivity
with CT has been reported to be as high as
97%9dsignificantly higher than that of RT-PCR alone,
particularly during early phases of disease.10 A direct
comparison of the 2 detectionmethods among 1014Wuhan
patients resulted in positive confirmations among 88%with
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CT imaging versus 59% with RT-PCR, and up to 93% of
patients were deemed positive with CT before confirmation
via RT-PCR testing.9 That being said, specificity of CTwas
25% alone9; thus, imaging serves as more of a complement
to rapid detection before RT-PCR confirmation.
Volumetric imaging with CT-on-rails (CTOR) or cone
beam CT (CBCT) is commonly employed in patients
undergoing radiation therapy as part of daily alignment.
Previous reports have shown that imaging as part of a
radiation therapy treatment course may identify non-
oncologic findings such as effusion, postobstructive atel-
ectasis, or infection. Likewise, posttreatment imaging
after radiation therapy often identifies well-characterized
imaging changes such as radiation pneumonitis.11-13 Such
imaging findings may often be confounded with infection
and may be particularly problematic when assessing pa-
tients at risk for COVID-19.
This case series describes the presentation of SARS-
CoV-2 infections among oncologic patients undergoing
radiation therapy from a multi-institutional group of ra-
diation oncology centers in the United States. In this
article, we highlight the clinical symptoms, daily imaging
findings, potential confounders, and clinical workflow to
triage these patients to the next level of care.
Cases
Case 1
Case 1 was a 63-year-old woman, a former smoker
without significant comorbidities, with recurrent adeno-
carcinoma who presented for definitive stereotactic abla-
tive radiation therapy to 50 Gy in 4 fractions for a 7-mm
tumor of the left upper lobe.14 CTOR, obtained for image
guidance and patient set-up before treatment delivery,
revealed new multifocal ground glass opacities (GGOs) of
the bilateral lungs, compared with her CT-simulation scan
obtained just 20 days beforehand for treatment planning
(shown in Fig 1). The treatment was performed (before
the first of 4 planned fractions), and she was referred to
the emergency department with the CTOR images
uploaded into the patient’s electronic health record for
provider review. Although the patient was asymptomatic
without fever or acute respiratory symptoms and her ex-
amination was unremarkable, she tested positive for
SARS-CoV-2 via nasopharyngeal swab RT-PCR. Upon
notification, the patient was instructed on home quaran-
tine precautions, and treatment was subsequently deferred
as per departmental policy. All staff members involved in
her treatment were rapidly notified, screened, and cleared
without quarantine. Of note, a repeat test 18 days later
again returned as positive, despite the absence of symp-
tom development. She has been tentatively rescheduled
for another CT simulation for treatment replanning 14
days after this second positive test, assuming she remains
asymptomatic during this interval.
Case 2
Case 2 was a 64-year-old woman who presented in early
February with a diagnosis of cT1bN0M0 left upper lobe
non-small cell lung cancer, diagnosed after surveillance
lung CT demonstrated growth of a nodule. The patient’s
past medical history was significant for chronic obstructive
pulmonary disease (% of forced expiratory volume at 1
second [FEV1] predicted at 63%, and % of diffusion ca-
pacity for carbon monoxide [DLCO] predicted of 42%).
She had a history of being a former smoker, with a 70-pack
year history. Based on the nodule’s growth on surveillance
Figure 1 The reference image on the right represents the computed tomography (CT) simulation study obtained 20 days before the
start of stereotactic body radiation therapy (SBRT) to a left upper lobe non-small cell lung cancer (NSCLC). The daily CT-on-rails
(CTOR) imaging from the first fraction of treatment demonstrated new bilateral multifocal ground glass opacities concerning for
coronavirus disease 2019 (COVID-19) infection.14
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lung CT and fluorodeoxyglucose-avidity on positron
emission tomography and CT (30.3), a clinical diagnosis of
non-small cell lung cancer was made. After the patient was
deemed to be a high-risk operable candidate, she was
recommended for stereotactic body radiation therapy
(SBRT) as definitive management. She underwent CT
simulation in mid-March for SBRT (55 Gy/5 daily
consecutive fractions), and her first treatment was deliv-
ered 10 calendar days later. However, at the time of her on-
treatment visit the patient reported increased severity of her
baseline cough and shortness of breath, several episodes of
posttussive emesis, and increased fatigue not relieved by
rest. On review of her CBCT imaging, it was found that she
had new GGOs in the right lower lobe (Fig 2). Based on
these symptoms and findings, the institution’s COVID
hotline was immediately notified on April 1, 2020. How-
ever, because the patient did not meet the criteria at that
time for COVID-19 screening (fever, sick contacts, or
travel), she was not recommended for testing. Given the
continued clinical concern for both her symptoms and new
findings on CBCT, direct communication was made with
an infectious disease physician at the institution, who
recommended she be treated as a presumed COVID-19-
positive patient, and she was approved for testing. She
was given a mask and instructed to start home quarantine.
Three days later her test returned as negative for SARS-
CoV-2 RNA. However, given the continued high index
of suspicion for COVID-19, the patient remains in quar-
antine, with a plan to complete her final 2 fractions of
SBRT once she has been asymptomatic for 3 days. The
new imaging findings are still attributed to her potential
COVID-19 diagnosis, in the absence of any confirmed
alternative.
Case 3
Case 3 was a 66-year-old woman with T1bN2M0,
stage IIIA small cell lung cancer of the right upper lobe.
The patient’s medical history includes emphysema,
obstructive sleep apnea, and nonspecific pulmonary
nodules that had been followed on chest CT, ultimately
leading to the current diagnosis. The patient was a
former smoker who quit over a decade ago but had a 74-
pack-year smoking history. The patient was treated with
curative intent twice-daily thoracic radiation therapy
concurrent with carboplatin and etoposide. All institu-
tional radiation dose-volume parameters were within
tolerance, the mean lung radiation dose was 9.3 Gy, and
the volume of lung receiving 20 Gy was 19.8%.
Chemoradiation was well tolerated with acute toxicities
including grade 1 cough and grade 1 esophagitis.
Approximately 9 weeks after radiation therapy, the pa-
tient called reporting a 2-day history of a new nonpro-
ductive cough with increased dyspnea and increased use
of albuterol. The patient denied fever, fatigue, or a
decreased appetite. The patient asked if her current
symptoms could be toxicities from her radiation treat-
ment. At the time of her call, there was an intensification
of the local COVID-19 epidemic. The patient was
counseled on radiation pneumonitis (RP) and the po-
tential need to start treatment with a high-dose corti-
costeroid taper. No repeat imaging was obtained at the
time. However, out of caution she was recommended to
undergo testing for COVID-19. The COVID-19 quali-
tative RNA test returned positive. The patient was not
treated for RP, but rather, referred for COVID-19
management.
Figure 2 The first image is an axial image from the computed tomography (CT) simulation study of case 2, obtained 9 days before
start of stereotactic body radiation therapy (SBRT) to the left upper lobe lesion (not shown). The second image is the cone beam CT
(CBCT) taken before the first fraction of treatment. On day 2, the patient began to experience increasing shortness of breath and cough.
On the third fraction of treatment, peripheral ground glass opacities were seen in the right upper lobe, out of the treatment field, which
were new compared with the first 2 images shown here.
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Discussion
Radiation oncology clinics around the world are
currently working diligently to protect both patients and
staff from the morbidity and mortality of COVID-19.15,16
However, this pandemic has presented at a time when
many patients are either beginning or currently receiving
cancer treatment. There continues to be a fine balance
between triaging patient symptoms (which for thoracic
patients may have some overlap with COVID-19 symp-
toms) and not introducing delays in oncologic care. In this
series of teaching cases, we presented a range of pre-
sentations of COVID-19. Although the cases here repre-
sent patients who had both positive and negative COVID-
19 testing, it should be noted that even patients with
negative testing were still clinically managed as presumed
positives with home quarantine and symptom
surveillance.
Incidental imaging findings suspicious for COVID-19
on diagnostic chest CTs have been increasingly re-
ported.17 Early features described to date include bilateral
peripheral GGOs, which can be multifocal or multilobar
in appearance.18-20 With increasing clinical severity, im-
aging demonstrates increased extent, density, and number
of these GGOs.21,22 Resolution is accompanied by
decrease and resorption of nodular opacities bilaterally.
The use of CT image guidance for patients receiving
radiation therapy to the chest or thorax for lung, esoph-
ageal, and breast malignancies presents a unique oppor-
tunity to screen for COVID-specific lung changes. This
was recently highlighted as a case study on the Radiation
Oncology Incident Learning System (RO-ILS).23 Rec-
ommendations from RO-ILS included having radiation
therapists, physicists, dosimetrists, and physicians
become familiar with and screen for these characteristic
COVID-19 findings daily and triage patients with findings
for further evaluation. It was also recommended that
clinical practices report these events to RO-ILS to help
determine the prevalence of these findings.
Note that a prudent differential is still necessary, as
patients being treated for thoracic malignancies may have
significant baseline pulmonary comorbidities. Addition-
ally, patients who have a history of systemic therapy,
particularly immunotherapy, may also have pulmonary
parenchymal changes over time.24 However, as shown in
the cases presented here, the rapidity of infiltrate
appearance on treatment should prompt immediate
attention by the treating physician for symptom screening,
vital signs, and appropriate triage to institutional COVID
testing. Conversely, negative CBCTs should not be used
to clinically “clear” patients who are having other
COVID-associated symptoms, such as fever, new or
worsening cough, new or worsening shortness of breath,
or pleuritis. In a retrospective series of more than 120
COVID-19-positive patients across 4 medical centers in
China, diagnostic CT images were compared by duration
of time between symptom presentation and imaging.25
For patients receiving CT imaging 0 to 2 days from
initiation of symptoms, 56% of these “early scans” were
negative, whereas only 10% of intermediate scans at 3 to
5 days from symptoms and 4% of late scans at 6 to 12
days from symptoms were negative. Therefore, pre-
screening of patient symptoms via nursing staff before CT
simulation study and daily screening questions before
treatment still represent a crucial part of clinical practice.
Another clinical scenario presented here illustrates the
need to have a high index of suspicion for COVID-19 for
patients who are weeks to months out from the time of
completion of thoracic radiation therapy. During this
pandemic, patients with a history of thoracic radiation
therapy who are suspected of having RP require attention.
The characteristic symptoms of RP include progressive
shortness of breath, cough, and fatigue, with or without a
low-grade fever occurring weeks to several months after
thoracic radiation. These symptoms overlap with those of
COVID-19. Given the increasing prevalence of COVID-
19, patients who present for RP evaluation should be
tested for COVID-19, especially if they are to be started
on empirical high-dose corticosteroids. Data indicate that
corticosteroid therapy can worsen COVID-19-associated
lung injury.26 Additionally, careful review of chest CT
imaging, if available, is recommended given that the
diffuse and multilobar radiographic features of COVID-
1927 contrast with the classic CT appearance of RP that is
mostly limited to the radiation field.
Patients actively undergoing radiation therapy should
have treatment paused upon suspicion for COVID-19,
pending screening test results. For those who test positive,
robust data are lacking regarding the appropriate time-
frame for radiation therapy resumption. The Centers for
Disease Control has provided guidelines on nontesting
strategy criteria for ending transmission-based pre-
cautions in the health care setting,28,29 which may be
adopted for these scenarios pending stronger evidence. A
test-based strategy is also outlined requiring 2 consecutive
negative test results (collected at least 24 hours apart),
although implementation may be limited owing to lack of
test availability and capacity. Per nontesting strategy for
symptomatic patients (case 2), Centers for Disease Con-
trol requirements entail the passage of (a) 7 days since
first appearance of symptoms and (b) 3 days since re-
covery (defined as resolution of fever and improvement of
respiratory symptoms). However, these guidelines are
admittedly specific to isolation. Thus, more stringent
criteria and timeframes may be warranted for patients
with active cancer. As for asymptomatic patients (case 1),
our institution requires 14 days to pass from first posi-
tive COVID-19 result (typically without need for retest-
ing), although this 14-day timeline was cautiously
reapplied toward the patient’s second positive test date
(ordered through her local provider).
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Although usual treatment volume has decreased at
many radiation oncology centers during the COVID-19
pandemic, there are still many patients who have recently
received treatment or are currently on treatment. Although
measures such as screening questions and temperature
measurements before department check-in certainly play a
crucial role in appropriate patient triage, we are in a
unique position to use an additional resource to monitor
our high-risk patients with on-treatment daily CT imag-
ing. Although this manuscript described 3 scenarios for
patients with thoracic malignancies, we would recom-
mend that both the initial simulation CT and on-board
CTs acquired as part of daily image guidance of any
patient where the imaging field of view encompasses the
chest be reviewed for new or increasing infiltrates,
particularly in patients with new symptoms. The entire
image set should be reviewed, superiorly to inferiorly, to
assess for potential changes. Owing to the observation
that radiologic changes may precede physical symptoms,
and considering a false negative rate ranging from 10% to
30%,9 this routine part of our daily cancer care gives us an
additional tool to monitor our patients during this un-
precedented time.
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